acute- and post-myocardial infarction, and congestive heart failure. However, β blockers do not all share the same clinical outcomes with respect to efficacy or safety in many of these conditions.

The findings hint at why the ABYSS trial failed to show it was safe to stop beta-blockers after an MI in stable patients.

Beta blockers have been shown to prolong survival in chronic heart failure. It is currently a matter of debate whether any β blocker is superior to the other in terms of improving symptoms ...

Aficamten was associated with improved peak oxygen uptake and a tolerable safety profile vs. metoprolol, a beta-blocker, in ...

Patients with COPD and established cardiovascular disease have more MACEs and seek less preventive cardiac care than patients with CVD alone.

A new study has found that, for most of us, the fiber we eat can protect our heart health, lowering the risk of high blood ...

and heart failure. Symptoms and treatments depend on the type of heart disease someone has. According to the Centers for Disease Control and Prevention (CDC), heart disease is the leading cause of ...

Community cardiology specialist Dr Peter Savill discusses five key challenges for GPs in the management of atrial ...

The FDA has granted a breakthrough device designation to the BiVACOR Total Artificial Heart. Made of titanium, the device uses a magnetically levitated rotor to pump blood in adult patients with ...

The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection ...

Bayer and Merck & Co’s heart failure drug vericiguat has been approved by the FDA under the brand name Verquvo, in an increasingly competitive market. Verquvo has been approved to reduce risk of ...

attending our heart failure clinic between 2002 and 2004, was conducted. Serum creatinine and haemoglobin levels checked during 12 months before and 12 months after the initiation of β blocker ...